Pectasides, D., Papaxoinis, G., Kalogeras, K. T., Eleftheraki, A. G., Xanthakis, I., Makatsoris, T., . . . Fountzilas, G. (2012). XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: A Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BioMed Central.
Chicago Style CitationPectasides, Dimitrios, et al. XELIRI-bevacizumab Versus FOLFIRI-bevacizumab As First-line Treatment in Patients With Metastatic Colorectal Cancer: A Hellenic Cooperative Oncology Group Phase III Trial With Collateral Biomarker Analysis. BioMed Central, 2012.
Cita MLAPectasides, Dimitrios, et al. XELIRI-bevacizumab Versus FOLFIRI-bevacizumab As First-line Treatment in Patients With Metastatic Colorectal Cancer: A Hellenic Cooperative Oncology Group Phase III Trial With Collateral Biomarker Analysis. BioMed Central, 2012.